What are the opening hours?

Monday 8am - 5pm Tuesday 8am - 5pm Thursday 8am - 5pm Friday 8am - 5pm

Dr. Isreb- The Integrative Nephrologist, Vancouver, WA (2026)

04/26/2026

🧂🫘 Blog Highlight: Dietary Phosphorus and Kidney Health

Phosphorus is an essential nutrient required for bone structure, cellular energy production (ATP), nerve signaling, and heart function. The average adult needs roughly 900–1250 mg per day to support normal physiology.

But in chronic kidney disease (CKD), phosphorus metabolism becomes increasingly difficult for the kidneys to regulate.

Normally, the kidneys maintain phosphorus balance through filtration and reabsorption, guided by hormones such as parathyroid hormone (PTH), vitamin D, and fibroblast growth factor-23 (FGF-23).

As kidney function declines, this regulatory system begins to break down. The body compensates by increasing PTH and FGF-23 to push the kidneys to excrete more phosphorus. Over time, however, the kidneys can no longer keep up.

Excess phosphorus then begins to accumulate in the body, leading to:

• Vascular calcification
• Inflammation
• Bone disease (CKD-MBD)
• Increased cardiovascular risk

One of the most important and often overlooked factors is the source of dietary phosphorus.

• Processed foods contain inorganic phosphorus additives that are absorbed almost 100%.
• Animal proteins have moderate absorption (~60%).
• Plant foods contain phosphorus bound to phytates, which humans absorb far less efficiently (~40%).

This means that two diets with similar phosphorus content may have very different biological effects depending on food sources.

It also explains why many researchers now support whole-food plant-forward diets for kidney health.

This raises some interesting questions:

Should we focus less on total phosphorus intake and more on phosphorus bioavailability?
How much do phosphate additives in processed foods contribute to CKD progression?
And should phosphorus labeling become more transparent in food products?

What strategies do you find most effective in managing phosphorus intake in kidney patients?

Let’s discuss in the comments below👇

Read the full blog here: [https://inkidney.com/dietary-phosphorus-and-kidney-health/]

04/25/2026

🦴🫘 Blog Highlight of the day: Vitamin A and Bone Disease in CKD

Bone and mineral disorders are among the most common complications of chronic kidney disease (CKD). Much of the discussion typically focuses on vitamin D, calcium, phosphorus, and vitamin K2, but another nutrient is increasingly being examined: vitamin A.

Vitamin A is essential for many biological processes, including immune function, vision, and cellular growth. In bone health, it plays a key role in bone remodeling, the process where old bone is broken down and new bone is formed.

At normal levels, vitamin A helps regulate this balance by supporting osteoclast activity needed for healthy bone turnover. However, research shows that excess vitamin A can overstimulate bone resorption, leading to weaker bones and a higher risk of fractures.

Interestingly, studies have found a U-shaped relationship with vitamin A and bone health. Both too little and too much vitamin A may increase fracture risk.

This becomes particularly relevant in kidney disease. As kidney function declines, vitamin A levels often rise naturally because the kidneys help regulate its metabolism. In advanced CKD, elevated vitamin A levels may contribute to CKD-associated mineral and bone disorder (CKD-MBD), a condition involving abnormal bone turnover and vascular calcification.

Another layer of complexity involves the interaction between vitamin A and vitamin D, since excess vitamin A may reduce vitamin D–mediated calcium absorption.

These findings raise important questions:

Should vitamin A supplementation be avoided in advanced CKD?
How should clinicians balance the role of vitamin A with vitamin D and K in bone health?
And could nutrient interactions be an underrecognized driver of CKD-related bone disease?

What is your experience managing bone health in CKD patients?

Let’s discuss below👇

Read the full blog here: [https://inkidney.com/vitamin-a-in-bone-disease-associated-with-chronic-kidney-disease/]

04/24/2026

Did you know 1 in 800 people live with polycystic kidney disease (PKD)—the most common inherited kidney disorder?

Those fluid-filled cysts don’t just sit there… they grow, compress the kidneys, and lead to progressive loss of function. 😰

But there’s more to PKD than just the diagnosis. How do you manage it? What diet and lifestyle changes really help? Which medications are worth discussing with your doctor?

We created our PKD Protocol to answer these questions and more. Inside, you’ll find:

🧠 How to assess and monitor PKD
📊 Risk stratification tips
🥦 Lifestyle & nutrition guidance
💊 Medication considerations

… all backed by science, and designed for both patients and healthcare providers.

👉 What’s been your biggest challenge managing PKD?
👉 What do you wish you had known sooner?

Drop a comment below and let’s learn from each other. 👇

Ready to dive deeper?
Download the PKD protocol here:🔗

https://f.mtr.cool/vajfimqmhm

04/23/2026

⚠️🫘 Blog Highlight: Lead Exposure and Kidney Health

Lead exposure is often thought of as a problem from the past. Yet chronic low-level exposure remains common worldwide, and growing evidence suggests it may quietly contribute to kidney disease.

Lead can enter the body through multiple sources, including:

• Older homes with lead-based paint
• Contaminated drinking water from aging pipes
• Certain cosmetics, jewelry, and toys
• Occupational exposure (welding, batteries, ceramics)
• Environmental exposure such as aviation fuel near airports

Once absorbed, lead cannot be broken down by the body. Instead, it is either stored in bone for decades or eliminated primarily through the kidneys.

Because the kidneys are responsible for clearing lead, they are also one of the organs most vulnerable to its toxic effects.

Research shows that lead can:

• Damage kidney tubules through oxidative stress and mitochondrial injury
• Interfere with calcium signaling and cellular function
• Reduce the kidneys’ ability to eliminate uric acid
• Promote tubulointerstitial inflammation and fibrosis

Over time, this can contribute to the well-known triad associated with chronic lead exposure:
• Progressive kidney disease
• Elevated blood pressure
• Increased risk of gout

Interestingly, nutrition appears to influence how the body handles lead. Iron and calcium deficiencies can increase lead absorption, while adequate mineral intake may help reduce toxicity.

Genetics and even the gut microbiome may also influence individual susceptibility to lead exposure.

This raises some important questions:

How much environmental toxin exposure contributes to chronic kidney disease?
Should heavy metal exposure be evaluated more routinely in kidney patients?
And can nutrition and detoxification strategies meaningfully reduce long-term risk?

Environmental health may be a larger part of kidney disease prevention than we once realized.

What are your thoughts on the role of environmental toxins in kidney disease?

Let’s discuss below👇

Read the full blow: [https://inkidney.com/lead-exposure-and-kidney-health/]

04/22/2026

🦠🫘 Blog Highlight: The Gut–Kidney Toxin Connection

When we think about toxins in chronic kidney disease (CKD), we usually think about waste products that the kidneys can no longer filter. But many of these compounds may actually originate in the gut.

The gut–kidney axis describes the complex relationship between microbiome balance, intestinal barrier health, inflammation, and kidney function.

In a healthy gut, microbes help process nutrients and produce beneficial metabolites. But when the microbiome becomes imbalanced (dysbiosis), certain bacteria begin producing compounds that become uremic toxins.

Researchers have identified more than 60 gut-derived uremic toxins, with several strongly linked to CKD progression and cardiovascular risk:

• Indoxyl sulfate (IS)
• p-Cresyl sulfate (pCS)
• Trimethylamine-N-oxide (TMAO)
• Indole acetic acid (IAA)

As kidney function declines, these toxins accumulate, increasing inflammation, vascular damage, and kidney injury, which further worsens the microbiome imbalance. This creates what researchers call the gut–kidney dysbiosis cycle.

Diet may play a key role. Diets high in red and processed meat appear to increase toxin production, while fiber-rich plant foods support beneficial microbes.

This raises important questions:

Should gut health be a central part of CKD management?
Can diet meaningfully reduce uremic toxin production?
And how much of kidney disease progression is microbiome-driven?
What’s your perspective on the gut–kidney connection?

Let’s discuss below 👇

Read the blog below: [https://inkidney.com/the-gut-derived-uremic-toxins/]

04/21/2026

Kidney stones are often treated as a one-time event.

But in reality, recurrence is common.

After a first episode, the likelihood of another stone within 5–10 years is close to ...?

The question is not just how to treat stones when they occur, but also how to reduce the risk of their recurrence.

More on this approach in Integrative Nephrology.

What is your guess? Tell me below 👇

04/20/2026

🫘🔬 Study Highlight:

Higher Serum Osmolality Signals Faster Kidney Decline in ADPKD

In autosomal dominant polycystic kidney disease (ADPKD), predicting who will experience faster kidney decline is critical.

This prospective study followed 311 ADPKD patients for five years, with evaluations every six months, to determine whether serum and urinary osmolality could predict kidney outcomes.

The results were striking.

Patients with higher serum osmolality had nearly a sixfold higher risk of experiencing a 40% decline in eGFR compared with those with the lowest osmolality levels.

Serum osmolality also showed strong predictive ability for kidney decline.

In contrast:

• Urinary osmolality showed an inverse relationship with outcomes
• It performed poorly as a predictive marker for disease progression

Why this matters

ADPKD treatments increasingly focus on reducing vasopressin signaling, a hormone closely linked to body osmolality and cyst growth.
Higher serum osmolality may reflect greater vasopressin activity, which can drive:

• 💧 Increased cyst growth
• 🫘 Faster kidney function decline
• 🧪 Greater disease progression risk

An important takeaway is that serum osmolality is simple, inexpensive, and widely available.

It may serve as a practical clinical surrogate for vasopressin activity, especially in settings where specialized biomarkers like copeptin are not readily accessible.

Sometimes the most useful clinical clues are already hiding in routine labs.

Do you routinely look at serum osmolality trends in ADPKD patients?

Let’s discuss 👇

Read the study: [https://journals.lww.com/kidney360/abstract/9900/the_relationship_of_osmolality_and_kidney_outcomes.883.aspx]

04/19/2026

🪨🫘 Blog Highlight: Electrolyte Imbalances and Kidney Stone Formation

Kidney stones affect millions of people and can lead to severe pain, obstruction, and long-term kidney damage if not addressed. While treatment often focuses on removing stones, preventing recurrence requires understanding why stones form in the first place.

About 75% of kidney stones are calcium oxalate stones, but the underlying drivers go far beyond calcium alone. Several electrolyte and metabolic factors influence the risk of stone formation:

• Calcium: High urinary calcium increases the chance that calcium will bind with oxalate to form crystals. Interestingly, restricting dietary calcium may actually increase risk because calcium normally binds oxalate in the gut and prevents its absorption.
• Citrate: One of the body’s most powerful natural inhibitors of stone formation. Citrate binds calcium in the urine and reduces crystal formation.
• Magnesium: Magnesium can bind oxalate and increase urinary citrate levels, helping lower the risk of calcium oxalate stones.
• Potassium: Low potassium levels are associated with reduced urinary citrate and increased calcium excretion, creating conditions that favor stones.
• Uric acid: Elevated uric acid can form stones directly and may also serve as a nucleus around which calcium oxalate crystals develop.

Hydration also plays a major role. When urine becomes concentrated, minerals are more likely to crystallize, which is why increasing water intake is a cornerstone of prevention.

These insights highlight an important idea: kidney stone prevention is not just about avoiding certain foods. It requires understanding electrolyte balance, diet, hydration, gut health, and genetics.

What strategies have you found most effective in preventing kidney stones?

Let’s discuss in the comments below👇

Read the full blog here: [https://inkidney.com/electrolyte-imbalances-and-kidney-stone-formation/]

04/18/2026

🧬🫘 New Blog Published Today

SGLT2 inhibitors have become one of the most important advances in modern nephrology. These medications slow the progression of chronic kidney disease, reduce heart failure hospitalizations, and improve cardiovascular outcomes.

But their effects extend beyond glucose control.

By blocking glucose reabsorption in the proximal tubule, SGLT2 inhibitors cause glycosuria, leading to the loss of 50–80 grams of glucose per day in the urine. This creates osmotic diuresis and changes the way the kidney handles water, electrolytes, and potentially micronutrients.

That raises an interesting question that is rarely discussed in clinical practice:

Could SGLT2 inhibitors influence nutrient balance?

Emerging research suggests several physiologic shifts may occur, including:

📌 Higher serum magnesium, which may support vascular and metabolic health
📌Changes in phosphate handling, with increases in FGF-23 and reduced vitamin D activation
📌 Shifts in amino acid handling and mitochondrial metabolism

There are theoretical effects that have not been studied thoroughly yet, such as:

👉 Potential effects on B vitamins, particularly thiamine, due to altered proximal tubule transport
👉 Possible changes in trace minerals, such as zinc

Most of these changes appear modest and are still being studied. However, they highlight something important:

Kidney medications often reshape the entire metabolic environment, not just one pathway.

Understanding how therapies interact with nutrition, metabolism, and kidney physiology may help us think more broadly about optimizing outcomes for patients with diabetes and CKD.

SGLT2 inhibitors remain one of the most powerful tools we have to slow kidney disease.

But as we learn more about their systemic effects, the intersection of pharmacology, nutrition, and kidney physiology becomes increasingly interesting.

💬 What do you think?

Should clinicians begin paying closer attention to nutrient balance in patients taking SGLT2 inhibitors?

Read the full blog here:
https://inkidney.com/sglt2-inhibitors-and-nutrient-balance

04/17/2026

We are beginning to understand kidney disease differently.

Not as an isolated organ problem, but as part of a broader network of interacting systems.

📌 Genetic testing is reshaping how we define disease.
📌 Metabolic health is increasingly central to progression.
📌 Sleep disorders and autonomic dysfunction are gaining recognition.
📌 Environmental exposures are no longer theoretical considerations.

And yet, these domains are still often addressed separately.

👉 Nephrology.
👉 Lifestyle medicine.
👉 Functional medicine.
👉 Genomics.

Each contributes meaningful insight. But in clinical practice, they rarely exist within a unified framework.

The next step for kidney care is not choosing between these approaches.

It is learning how to integrate them in a way that is structured, evidence-informed, and clinically applicable.

This shift is already underway.

04/16/2026

🧠🫘 Study Highlight of the day: Kidney Disease and Cognitive Decline

A new cohort study published in JAMA Network Open (2026) examined whether the severity of chronic kidney disease influences the risk of developing cognitive impairment.

Researchers followed 5,607 participants with CKD from the Chronic Renal Insufficiency Cohort (CRIC) study and tracked multiple cognitive domains over several years, including:
• Global cognition
• Verbal memory
• Attention and processing speed
• Executive function

One of the most striking findings was that proteinuria (measured as the urine protein-to-creatinine ratio) emerged as a stronger predictor of cognitive decline than kidney filtration alone.

For every standard deviation increase in urinary protein:

• Risk of impairment in attention and processing speed increased by 21%
• Risk of impairment in executive function increased by 16%

When proteinuria and reduced eGFR occurred together, the risk of global cognitive impairment rose even further.

These findings reinforce a growing idea in medicine: the brain and kidneys share many of the same vascular and metabolic vulnerabilities.

Protein leakage in the urine may not just be a marker of kidney injury. It may also signal systemic vascular and inflammatory processes that affect the brain.

This raises important questions for both clinicians and patients:

Should cognitive health be monitored more closely in people with CKD?
Could reducing albuminuria help protect not only the kidneys but also the brain?
And how early should we intervene to preserve cognitive function in kidney disease?

The kidney–brain connection may be more important than we once thought.

What has been your experience with cognitive changes in CKD patients?

Let’s discuss below 👇

Read the study here: [https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2845146 ]

04/15/2026

💊🫘 Blog Highlight: Kidney Medications and Hidden Nutrient Depletion

Medications are essential tools in kidney care. Drugs like ACE inhibitors, ARBs, diuretics, statins, and metformin have dramatically improved outcomes for patients with hypertension, diabetes, and chronic kidney disease.

But an often overlooked issue is drug–nutrient interactions.

Many commonly prescribed medications can deplete key vitamins and minerals or alter how the body uses them.

For example:

• ACE inhibitors and ARBs can increase potassium levels and contribute to zinc loss.
• Diuretics may lead to magnesium, potassium, folate, and B-vitamin depletion.
• Statins can reduce CoQ10, an essential compound for mitochondrial energy production.
• Metformin is well known to lower vitamin B12 absorption.
• Proton pump inhibitors can reduce magnesium, calcium, iron, and B12 absorption.

These changes may seem small at first, but over time they can affect energy production, cardiovascular health, sleep quality, bone metabolism, and immune function.

This raises an important clinical question:

Should medication management routinely include monitoring and correcting micronutrient status?

Integrative nephrology increasingly recognizes that optimal care is not only about prescribing the right medications, but also about supporting the body’s biochemical balance while those medications are used.

What has been your experience with drug–nutrient interactions in clinical practice or personal health?

Is this an area we should be paying more attention to?

What do you think? Let’s discuss 👇

Read the full blog here:

https://inkidney.com/kidney-medications-nutrients/

Dr. Isreb- The Integrative Nephrologist

04/26/2026

04/25/2026

04/24/2026

04/23/2026

04/22/2026

04/21/2026

04/20/2026

04/19/2026

04/18/2026

04/17/2026

04/16/2026

04/15/2026

Address

Opening Hours

Telephone

Website

Alerts

Contact The Practice

Shortcuts

Share

Category

Monday	8am - 5pm
Tuesday	8am - 5pm
Thursday	8am - 5pm
Friday	8am - 5pm